1、Solving the Efficiency Bottleneck of Target Validation to Accelerate Preclinical Drug Screening

• Structure: Low Target Screening Efficiency + Customized High-Throughput Panel Solutions
• Purpose: Directly address the efficiency bottleneck of pharmaceutical companies in the target validation stage, realize high-throughput and high-precision screening through customized target panels, and shorten the discovery cycle of drug candidates.

2、Service Overview

1. Positioning: As a core link in preclinical drug screening, target-based panel screening is a key step to verify the targeting and effectiveness of drugs.
2. Industry Pain Points: Traditional single-target detection is time-consuming and costly, difficult to meet the demand for parallel screening of multiple targets, and the cross-species target compatibility is insufficient.
3. Solution:Through customized target panel technology, integrate the capability of simultaneous detection of multiple targets, and combine with an automated platform to achieve efficient and highly reproducible screening of drug candidates, significantly reducing early R&D risks.

3、Our Services

1. 1.Customized Panels Based on Defined Targets

• Technical Methods: Design specific detection panels for known targets (e.g., VEGF, HER2, GPCR, EGFR, etc.), supporting simultaneous screening of over 100 targets.
• Application Scenarios: Primary screening of small molecule inhibitors/agonists, etc.
• Data Delivery: Provide IC50/EC50 values, dose-effect curves and target selectivity heatmaps.

2. 2.Pathway Panels Based on Defined Cancer Types

• Technical Methods: Integrate driver genes and drug resistance-related targets according to cancer types (e.g., lung cancer, gastric cancer) to construct tumor-specific pathway panels (Example: Lung cancer panel contains more than 10 targets such as EGFR/ALK/ROS1).
• Application Scenarios: Screening of tumor-targeted drugs, evaluation of combination therapy regimens.
• Data Delivery: Raw CCK-8/CTG data, proliferation inhibition dose-effect curves.

3 Customized “Blind Box” Panels

• Technical Methods: Flexibly combine targets according to customer needs, supporting cross-species (human/murine) target compatibility testing.
• Application Scenarios: Functional verification of new targets, research on indication expansion.

4、Technology Platforms and Advantages

3.1 Technology Platforms

• CRISPR Tool Cell Platform: 293T/HELA tool cell lines support efficient gene editing to ensure target stability (sgRNA endogenous activity ≥90%).
• Stable Cell Line Construction Platform: Shorten the construction cycle of overexpression/knockdown stable cell lines to 4-6 weeks, supporting STR verification of monoclonal cell lines.
• High-Throughput Detection Platform: Integrate an automated liquid handling system, supporting a daily detection throughput of over 10,000 tests in 96-well plates.

3.2 Differentiated Advantages

• Support for Integrated Screening of Primary Tumor Cells: Combine PDX-derived primary cells to simulate the in vivo
• Cross-Platform Data Compatibility: Detection results can be directly connected to CDX/PDX drug efficacy models to accelerate in vitro-in vivo

5、Service Process

1. Demand Communication (1 working day): Customize target panel solutions and confirm detection indicators (e.g., proliferation/apoptosis/migration).
2. Experiment Execution (2-4 weeks):

• Cell Culture: Cell expansion completed in SPF-grade laboratories.
• High-Throughput Screening: Real-time sharing of detection progress (raw data available on the online platform).

3. Data Delivery (1 week): Provide GLP-aligned standard reports, including dose curves, statistical analysis and RAW data.

6、Quality Control and Compliance

Compliance Standards: Meet the preclinical research specifications of FDA/EMA/NMPA, and experimental procedures follow GLP-aligned standards.

Quality Control Measures:

• STR identification of cells and negative mycoplasma test results.
• Double-blind review of data and third-party verification of key experiments

7、Case Studies

Case 1: Screening of Lung Cancer Targeted Drugs

• Customer Demand: Screen alternative solutions for EGFR-TKI-resistant cell lines.
• Solution: Customize a panel covering MET/RET/MTOR pathways and screen a compound library of over 10,000 compounds.
• Results:

• Identified 3 lead compounds (IC50<100nM) with a TGI of 68% (Attached figure: Tumor growth curve).

View the complete case.

8、Cooperation Advantages

• Customization Flexibility: Support on-demand customization from single-target to multi-pathway panels to adapt to the needs of different R&D stages.
• Efficiency Advantage: Standardized processes shorten the screening cycle by 30%, and urgent projects can be launched within 72 hours.
• End-to-End Support: Can be connected to in vivo CDX/PDX model verification, providing a full-chain service from target screening to IND application.

9、FAQ

Q1: Is cross-species target validation supported?

A: Yes, simultaneous detection of human/murine targets is supported.

Q2: Can the data delivery cycle be compressed?

A: The standard cycle is 4 weeks, and the urgent plan can be shortened to 2 weeks (additional sample size evaluation required).

10、Laboratory Highlights

• The SPF-grade cell room supports the processing of over 1,000 samples per day to ensure data consistency.
• View more laboratory facilities.

View More

11、Contact Us

• 24/7 Consultation: 3691125803@qq.com| +86 18802035152
• Get Customized Solutions Now: Free technical consultation
• Resource Download: White Paper on High-Throughput Screening Technology